Version history

{
  "session_id": "sess_SDA-TEST-PREREG-003_task_fcb59e84",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration\n\n## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease\n\n**Title:** TREM2 agonism will reduce amyloid-associated neurotoxicity by promoting microglial phagocytosis and metabolic reprogramming\n\n**Mechanism:** TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglia-specific receptor essential for microglial response to amyloid plaques. Agonist-mediated activation enhances amyloid clearance, reduces dystrophic neurites, and shifts microglia from a disease-associated (DAM) to homeostatic state.\n\n**Target Gene/Protein/Pathway:** TREM2 → DAP12 → SYK signaling → metabolic reprogramming (glycolysis shift) → enhanced phagocytosis\n\n**Supporting Evidence:**\n- TREM2 R47H variant increases AD risk ~3-fold (PMID 24121985)\n- TREM2-deficient mice show impaired microglial enclosure of amyloid plaques (PMID 29548884)\n- Human PET imaging: TREM2 expression correlates with amyloid burden (PMID 31253634)\n- TREM2 agonistic antibody (AL002c) shows efficacy in 5xFAD mice (PMID 32109293)\n\n**Predicted Experiment:** Treat 6-month 5xFAD mice with TREM2 agonist antibody (AL002c, 10mg/kg weekly IP) for 3 months. Measure:\n- In vivo: Amyloid PET (¹⁸F-AZD4694) reduction\n- Ex vivo: Iba1+ cell coverage of plaques (immunohistochemistry)\n- Behavioral: Morris water maze consolidation\n- Molecular: RNAseq of sorted CD11b+ microglia (DAM signature genes)\n\n**Confidence:** 0.78\n\n---\n\n## Hypothesis 2: NLRP3 Inflammasome Inhibition Attenuates Neurodegeneration via IL-1β Suppression\n\n**Title:** Chronic NLRP3 inhibition will prevent synapse loss in early-stage Alzheimer's disease through reduction of interleukin-1β mediated spine pruning\n\n**Mechanism:** NLRP3 inflammasome activation in microglia releases active IL-1β, which drives synapse elimination through complement cascade upregulation (C1q, C3). Inhibition blocks this pathway, preserving synaptic density.\n\n**Target Gene/Protein/Pathway:** NLRP3 → ASC → CASP1 → IL-1β → C1q/C3 upregulation → complement-mediated spine pruning\n\n**Supporting Evidence:**\n- NLRP3 KO mice protected from cognitive deficits in 3xTg AD model (PMID 26675736)\n- IL-1β infusion causes spine loss in healthy mice (PMID 24489802)\n- MCC950 (NLRP3 inhibitor) crosses BBB and reduces neuroinflammation (PMID 30638571)\n- Active caspase-1 observed in AD human brains (PMID 12408820)\n\n**Predicted Experiment:** 5-month APP/PS1 mice treated with MCC950 (50mg/kg/day in drinking water) for 2 months. Assess:\n- Behavioral: Novel object recognition (episodic memory)\n- Biochemical: Soluble Aβ42 (ELISA), mature IL-1β (meso scale)\n- Morphological: Cortical dendritic spine density (Golgi-Cox)\n- Electrophysiology: Long-term potentiation in hippocampal slices\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 3: TFEB-Mediated Autophagy Enhancement for α-Synuclein Clearance\n\n**Title:** TFEB nuclear translocation will reduce α-synuclein pathology by upregulating autophagosome-lysosome pathway genes\n\n**Mechanism:** Transcription Factor EB (TFEB) is master regulator of lysosomal biogenesis. Forced nuclear localization using AAV9-TFEB(S211A) (phosphorylation-deficient mutant) will induce transcription of autophagy-lysosomal genes, enhancing clearance of toxic α-synuclein oligomers.\n\n**Target Gene/Protein/Pathway:** mTORC1 inhibition → TFEB dephosphorylation → nuclear translocation → CLEA (autophagy/lysosome) gene transcription\n\n**Supporting Evidence:**\n- TFEB overexpression reduces α-synuclein aggregation in BAC transgenic mice (PMID 24185427)\n- mTORC1 inhibition (rapamycin) enhances α-synuclein clearance (PMID 17442627)\n- PBAE nanoparticle-mediated TFEB delivery reduces polyQ aggregation (PMID 29890108)\n- Autophagy-lysosome pathway genes downregulated in PD substantia nigra (PMID 28794040)\n\n**Predicted Experiment:** Bilateral striatal injection of AAV9-hTFEB(S211A) in 12-month M83 α-synuclein transgenic mice (10⁹ genomic copies, 2μL/hemisphere). 3-month survival:\n- Behavioral: Rotarod, cylinder test (motor function)\n- Biochemical: p62/SQSTM1, LC3-II (autophagy markers), α-synuclein pSer129 (ELISA)\n- Histological: p62+ aggregates, NeuN+ neuron count in substantia nigra\n- Survival endpoint: Incidence of paralysis\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 4: SIRT1 Activation as Mitochondrial Protective Strategy in ALS/FTD\n\n**Title:** SIRT1 activation will suppress C9orf72-mediated neurodegeneration by restoring mitochondrial homeostasis and reducing DPR accumulation\n\n**Mechanism:** C9orf72 repeat expansions produce toxic gain-of-function through bidirectionally transcribed RNA foci and five dipeptide repeat (DPR) proteins. SIRT1 activation promotes mitophagy (via PINK1/Parkin), reduces oxidative stress, and has been shown to decrease DPR levels in cellular models.\n\n**Target Gene/Protein/Pathway:** SIRT1 → PGC-1α deacetylation → mitochondrial biogenesis; SIRT1 → LC3 deacetylation → autophagy flux\n\n**Supporting Evidence:**\n- SIRT1 activator (SRT2104) extends survival in TDP-43 mice (PMID 26805578)\n- C9orf72 KO mice show mitochondrial dysfunction and lysosomal accumulation (PMID 25908856)\n- SIRT1 overexpression reduces poly-GR toxicity in Drosophila (PMID 31278169)\n- Resveratrol (SIRT1 activator) improves mitochondrial function in patient-derived motor neurons (PMID 29469839)\n\n**Predicted Experiment:** 8-week C9-BAC transgenic mice treated with SRT2104 (30mg/kg oral gavage, daily) until endpoint. Primary outcome:\n- Molecular: Expression of mitochondrial complex subunits (Complex I-V western blot), PGC-1α acetylation state\n- Behavioral: Grip strength, rotarod latency, nesting behavior\n- Histological: Motor neuron count (ChAT+ in ventral horn), Iba1+ gliosis\n- Survival: Cumulative survival analysis (log-rank test)\n- Tissue: DPR burden (poly-GA, poly-GR immunohistochemistry)\n\n**Confidence:** 0.68\n\n---\n\n## Hypothesis 5: CDK5 Dysregulation in Tau Pathology Propagation\n\n**Title:** CDK5 inhibition will block activity-dependent tau propagation by preventing phosphorylation of tau at S202/T205 and reducing exosome secretion\n\n**Mechanism:** Neuronal activity induces CDK5-dependent tau phosphorylation and packaging into exosomes. CDK5 inhibition (using dinaciclib or peptide inhibitors) will prevent this loading and reduce trans-synaptic tau spreading.\n\n**Target Gene/Protein/Pathway:** Neuronal activity → Ca²⁺ → p25/p35 → CDK5 activation → tau S202/T205 phosphorylation → exosome loading → extracellular spreading\n\n**Supporting Evidence:**\n- p25/CDK5 hyperactivity drives tau hyperphosphorylation in AD (PMID 15745994)\n- Exosome-mediated tau spread confirmed in human CSF (PMID 29072881)\n- Dinaciclib (CDK5 inhibitor) reduces tau phosphorylation in vivo (PMID 26593258)\n- Tau propagation requires neuronal activity (PMID 26863191)\n\n**Predicted Experiment:** P301S tau transgenic mice (12 months) receive stereotactic injection of AAV-dnCDK5 (dominant-negative) into entorhinal cortex, followed by optogenetic hippocampal stimulation (40Hz, 1hr/day for 4 weeks). Controls: AAV-GFP. Readouts:\n- Biochemical: p-tau S202/T205, total tau (Mab HT7), exosomal tau (NTA analysis)\n- Anatomical: Dentate gyrus p-tau burden (Stereology)\n- Cognitive: Contextual fear conditioning\n- In vitro: Primary neuron uptake of exosomes from treated vs. control mice\n\n**Confidence:** 0.74\n\n---\n\n## Hypothesis 6: NRF2 Antioxidant Pathway as Common Mechanism Across Neurodegeneration\n\n**Title:** NRF2 activation will provide neuroprotection across ALS, AD, and PD through restoration of glutathione-dependent redox buffering\n\n**Mechanism:** NRF2 (NF-E2-related factor 2) is master regulator of antioxidant response elements (ARE). Genetic or pharmacologic NRF2 activation (CDDO-EA, sulforaphane) will upregulate NQO1, HO-1, GCLM, and GSTA1, restoring redox homeostasis impaired in all major neurodegenerative diseases.\n\n**Target Gene/Protein/Pathway:** Keap1 oxidation → NRF2 release → nuclear translocation → ARE gene transcription → NQO1, HO-1, GCLM, GCLC, GSTA1\n\n**Supporting Evidence:**\n- NRF2 activation protects in MPTP mouse model of PD (PMID 29104108)\n- NRF2 activator (CDDO-TFEA) crosses BBB and extends ALS mouse survival (PMID 28467821)\n- NRF2 target gene polymorphisms associated with AD risk (PMID 20819947)\n- Post-mortem AD brain shows impaired NRF2 nuclear localization (PMID 23563891)\n\n**Predicted Experiment:** Triple disease model comparison: P301S tau mice, SOD1*G93A mice, MPTP-treated C57BL/6 mice. All treated with CDDO-EA (10mg/kg IP, 3x/week) starting at symptom onset. Shared readouts:\n- Motor: Rotarod, grip strength\n- Biochemical: GCLM expression, GSH/GSSG ratio, 4-HNE adducts\n- Survival (ALS model only)\n- RNAseq: ARE gene signature in motor cortex/ventral spinal cord\n\n**Confidence:** 0.76\n\n---\n\n## Hypothesis 7: Synaptic NMDAR Subtype Targeting to Prevent Excitotoxicity\n\n**Title:** GluN2A-containing NMDA receptor activation will prevent synapse loss better than broad NMDAR antagonism in Alzheimer's disease\n\n**Mechanism:** Excessive extrasynaptic NMDAR (GluN2B-containing) activation drives CREB shutoff and excitotoxicity, while synaptic NMDAR (GluN2A-containing) promotes survival signaling. Selective GluN2A activation or GluN2B inhibition will shift balance toward neuroprotection.\n\n**Target Gene/Protein/Pathway:** Synaptic NMDAR (GluN2A) → Ca²⁺ → CaMKII → CREB → BDNF expression → synaptic stability; Extrasynaptic NMDAR (GluN2B) → PP1 → pCREB shutoff\n\n**Supporting Evidence:**\n- Extrasynaptic NMDAR overactivation triggers synaptotoxicity in AD models (PMID 20371869)\n- Ifenprodil (GluN2B antagonist) prevents Aβ-induced dendritic spine loss (PMID 15229342)\n- TCN-201 (GluN2A antagonist at synaptic sites) worsens outcome, suggesting differential compartment effects\n- Memantine (partial NMDAR antagonist) preferentially blocks extrasynaptic receptors (PMID 17928558)\n\n**Predicted Experiment:** 6-month APP/PS1ΔE9 mice treated with ifenprodil (5mg/kg IP, daily) vs. vehicle vs. memantine (5mg/kg). 8 weeks treatment:\n- Electrophysiology: CA1 LTP (fEPSP slope)\n- Biochemical: pCREB S133, proBDNF/mature BDNF ratio, CaMKII autophosphorylation\n- Behavioral: Contextual fear conditioning, Y-maze spontaneous alternation\n- Histological: Synaptophysin+ puncta density (electron microscopy gold standard)\n\n**Confidence:** 0.65\n\n---\n\n## Summary Table\n\n| Hypothesis | Target | Primary Disease | Confidence | Evidence Quality |\n|------------|--------|-----------------|------------|------------------|\n| 1 | TREM2 | AD | 0.78 | High (multi-species) |\n| 2 | NLRP3/IL-1β | AD | 0.72 | Moderate |\n| 3 | TFEB | PD/LBD | 0.70 | Moderate |\n| 4 | SIRT1 | ALS/FTD | 0.68 | Moderate |\n| 5 | CDK5 | AD/FTD | 0.74 | Moderate-High |\n| 6 | NRF2 | All | 0.76 | High |\n| 7 | NMDAR subtype | AD | 0.65 | Moderate |\n\n---\n\n*Preregistration timestamp: [DATE] | Analysis plan: Two-way ANOVA (genotype × treatment) with Bonferroni correction for behavioral and biochemical endpoints. Sample size: n=12/condition (80% power for d=0.8). Blinded scoring for all histological endpoints.*",
  "tokens_used": "2756",
  "persona_id": "persona-theorist"
}